MedTech Intelligence – Read More
Peytant Solutions Inc. presented positive pre-clinical results of its AMStent® Tracheobronchial Covered Stent System at the 2025 American Association for Bronchology and Interventional Pulmonology (AABIP) Annual Meeting. Roy Joseph Cho, MD, MHA, associate professor of interventional pulmonology at the University of Minnesota, presented the pre-clinical outcomes of the FDA DeNovo cleared device. The AMStent is covered with decellularized human amniotic membrane (DCAM) and outperformed similar devices covered with a commercially available synthetic polymer, according to the company’s press release, Additionally, Ashutosh Sachdeva, M.D., associate professor of medicine, director of the interventional pulmonology program, and fellowship director in the Division of Pulmonary and Critical Care at the University of Maryland, featured the AMStent in his presentation “The Future: Novel Airway Stents”.
The AMStent device is designed to maintain airway patency and restore structure and function of the trachea or bronchial tree in patients with malignant obstructions caused by cancer while addressing challenges of synthetic-covered stents which can cause a foreign body response and resulting complications. When compared to a commercially available synthetic-covered stent in a pre-clinical study, the AMStent device demonstrated superior results, including less mucus buildup, integrating with airway tissue as early as day seven and achieving full integration by day 90, according to the study. In comparison, 33% of the control stents were fully occluded and showed significant airway complications throughout the study. The AMStents showed no stent migration while the control stents showed frequent migration, caused significantly less inflammation, and restored the structure and function of the epithelial layer. The results were obtained over a 90-day period in a porcine model.
The AMStent is an implantable airway prosthesis, delivered via a minimally invasive catheter system. The expandable tubular device is made of nitinol covered in a decellularized human amniotic membrane (DCAM), made from human amnion using Peytant’s proprietary Zymeric
process. Unlike synthetic coverings made of forever chemicals such as expanded polytetrafluoroethylene (ePTFE) or thermoplastic polyurethanes (TPUs), DCAM contains naturally occurring structural proteins like collagen, keratin, fibronectins, and laminins.
“We’re on a mission to fundamentally transform the treatment of luminal diseases using patented, foundational biomaterial technology,” said John Schorgl, Peytant Solutions’ cofounder, CEO, and board chair. “These results reinforce our belief that The AMStent system has the potential to set a new standard of care.”
Following its FDA De Novo granted clearance, Peytant is preparing to commercially launch the AMStent System in the U.S. later this year. Future research will explore its potential for other luminal applications, including vascular, gastrointestinal, neurological, and urological systems.
The post Positive Pre-Clinical Results for AMStent Pulmonary Obstruction System appeared first on MedTech Intelligence.
